Great presentation by Jordan at #PediatRxCon35

10/10 🧵Key Takeaways:
✅ Oral therapy expands treatment options for adolescents
✅ Single-day or single-dose options may improve adherence
✅ MINIMIZE resistance: use only in proven or strongly suspected bacterial causes
⚠️ Still essential⚠️
Safe sexual practices, testing, and partner treatment

9/10 🧵Blujepa Trial Review Continued:
• Noninferiority margin of 10%
• Microbiological Cure Rate:
- Gepotidacin: 92.6%, 95% CI 88–95.8 (n=187/202)
- Comparator: 91.2%, 95% Cl 86.4–94.7 (n=186/204)
- Difference: -0.1%, 95% CI -5.6–5.5

Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study - PubMed GSK and federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority.

8/10 🧵Blujepa Phase 3 Trial: shorturl.at/1SA0R
• Interventions (in both ITT and micro-ITT groups):
- PO gepotidacin 3g bid x 1day (n=314)
- IM ceftriaxone 500mg + PO azithromycin 1g (n=314)
• Mean age: 33.1 years (SD=10.22); range 17-64

7/10 🧵💊Blujepa (gepotidacin)💊
Package Insert: shorturl.at/jp8dO

•FDA approved for ≥ 45kg with limited or no alternative treatment options
•MOA: bacterial type II topoisomerase inhibitor
•Dose: 3g BID ×1 day with food
•Warnings: QTc prolongation,acetylcholinesterase inhibition, and C. diff

6/10 🧵 Nuzolvence Trial Review Continued:
• Noninferiority margin of 12%
- Authors’ reasoning: lack of treatments for MDR gonorrhea
• Microbiological Cure Rate:
- Zoliflodacin: 90.9%, 95% CI 88.1–93.3 (n=460/506)
- Comparator: 96.2%, 92.9–98.3 (n=229/238)
- Difference: 5.3%, 95% CI 1.4–8.6

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial - PubMed German Federal Ministry of Research, Technology and Space, UK Department of Health and Social Care as part of the Global Antimicrobial Resistance Innovation Fund, Japan Ministry of Health, Labour and Welfare, Netherlands Ministry of Health, Welfare and Sport and Directorate-General for International …

5/10 🧵Nuzolvence Phase 3 Trial: shorturl.at/Qbf2S
• Interventions:
- PO zoliflodacin 3g (n=621)
- IM ceftriaxone 500mg + PO azithromycin 1g (n=309)
• Mean age: 29.7 years (SD=9.4); range 15-73
- Only 10 adolescents included (15-17yo) with 9 in nuzolvence group

4/10 🧵⚠️Nuzolvence Warnings & Precautions⚠️
•Notable adverse events: neutropenia, leukopenia, and C. diff
•Utilize effective contraception for 3 months after administration
•May cause fetal harm in pregnancy
•May cause testicular toxicity and impair male fertility

3/10 🧵🍽️Nuzolvence Administration Considerations🍽️
*On empty stomach if <50 kg, with food if ≥50 kg*

Why? 🧐
It has an inverse relationship between body weight and drug exposure. Patients who weigh less already get higher drug exposure, and food increases the AUC ~1.5-2x

2/10 🧵💊Nuzolvence (zoliflodacin)💊
Package Insert: shorturl.at/ruf6S
FDA approved for uncomplicated urogenital gonorrhea for patients ≥35 kg

•MOA: bacterial type II topoisomerase inhibitor
•Dose: single 3g in 60mL water (use within 15 min)

FDA Approves Two Oral Therapies to Treat Gonorrhea The U.S. Food and Drug Administration recently approved two new oral medicines to treat a common sexually transmitted infection called gonorrhea.

🔁1/10 🧵 Pharmacy Update | 💬 ⚕️ By UConn P4 Nicole P
🚨 FDA Update (Dec 2025)🚨
Two new ORAL antibiotics, Nuzolvence (zoliflodacin) & Blujepa (gepotidacin), are now approved for uncomplicated urogenital gonorrhea in patients ≥12 years old

FDA News Release: shorturl.at/E0CpI

White text and PIDS logo on red background. Full statement as it appears on PIDS website.

PIDS applauds today’s momentous federal court finding that the dismissal and reconstitution of the ACIP and anomalous changes made by the Secretary of Health and Human Services to the childhood immunization schedule were likely unlawful. Statement: pids.org/2026/03/16/p...

Pediatric CAP Duration Update | UConn P4 💬 ⚕️🏥 By Nicole P
"How Long Should We Treat Pediatric Outpatient CAP? Rethinking Antibiotic Duration" Posted March 6, 2026
pharmacy.uconn.edu/pediatric-id...

Note these components are all different than what was included in the 2025-2026 flu vaccines.

Cell and Recombinant 2026-2027 influenza vaccine components:
- A/Missouri/11/2025(H1N1)pdm09-like virus;
- A/Darwin/1454/2025(H3N2)-like virus;
- B/Pennsylvania/14/2025 (B/Victoria lineage)

Egg Based 2026-2027 influenza vaccine components:
- A/Missouri/11/2025(H1N1)pdm09-like virus;
- A/Darwin/1454/2025(H3N2)-like virus;
- B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus

🧵FDA advisory committee has voted to recommend the following components for the 2026-2027 influenza vaccines

VRBPAC March 12, 2026 Meeting Announcement On March 12, 2026, the Committee will meet in open session to discuss and make recommendations on the strain composition of influenza virus vaccines for use in United States during the 2026-2027 influ...

Agenda and documents available here: www.fda.gov/advisory-com...

Vaccines and Related Biological Products Advisory Committee Meeting YouTube video by U.S. Food and Drug Administration

FDA having their influenza vaccine advisory committee meeting today to vote on products for the 2026-2027 season. This will also include information on current vaccine effectiveness and likely circulating strains. Meeting live at www.youtube.com/live/WKw0WEi...

Single-dose HPV vaccination in the United States — a multi-modeling analysis Evidence supporting the non-inferior efficacy of single-dose human papillomavirus (HPV) vaccination has prompted reconsideration of existing multi-dose HPV vaccination schedules. We evaluated the long-term health impact of adopting single-dose HPV ...

Applying the Data

1/2026: Multi-modeling analysis of HPV dosing

Models predicted 90% reduction by year 2100 in HPV infection and cervical cancer incidence with 1-dose regimen.

1-dose of HPV may become standard in the US soon

pmc.ncbi.nlm.nih.gov/articles/PMC...

#PedsIDsky #RXsky

Noninferiority of One HPV Vaccine Dose to Two Doses - PubMed One dose of either a bivalent or nonavalent HPV vaccine provided protection against HPV16 or HPV18 infection and was not inferior to two doses. (Funded by the National Cancer Institute and others; ESCUDDO ClinicalTrials.gov number, NCT03180034.).

New Literature

12/2025: Clinical Trial HPV 1 vs 2 dose series

Population: Girls 12-16 y/o in Puerto Rico (n= 20,330)

Results: Non-inferiority of 1 vs 2 doses; Difference of 0.21 infections/100 persons (95% CI, -0.09 to 0.51; P<0.001) pubmed.ncbi.nlm.nih.gov/41337735/

#PedsIDsky #RXsky

Guideline Recommendations for Healthy Pediatrics

AAP: 9-14 y/o- 2 doses, (if beginning series at >15 y/o- 3 doses recommended)

CDC: 1 dose at 11-12 y/o

WHO: 1-2 doses at 9-14 y/o

#PedsIDsky #RXsky

HPV Vaccination

88% decrease in HPV infections among 14-19 y/o females since vaccine introduction in 2006 Available product: (Gardasil 9) nonavalent vaccine Immunization can protect against HPV infection and related cancers

#PedsIDsky #RXsky

🔁 🧵 Pharmacy Update | UConn P4 HPV Immunization Review 💬 ⚕️💉 By Megan.

Another recent publication w/the PPA Immunization Committee, we highlight the importance of the hepatitis B vaccine at birth. 👶💉

🔗 jppt.kglmeridian.com/view/journal...

#PedsIDsky #Rxsky

Here is is our PPA Immunization Committee publication to support pharmacists in immunization practice. 💉📚

This article provides evidence-informed strategies and practical resources to strengthen vaccine conversations with families.

🔗 jppt.kglmeridian.com/view/journal...

#PedsIDsky #Rxsky

Peds ID and Immunization on Instagram: "Pediatric Bacterial Arthritis Takeaways for Pharmacy Practice by Kenna Riley available at: https://pharmacy.uconn.edu/pediatric-id-and-immunization-updates/" 0 likes, 0 comments - pedsidandimmunization on January 20, 2026: "Pediatric Bacterial Arthritis Takeaways for Pharmacy Practice by Kenna Riley available at: https://pharmacy.uconn.edu/pediatric-id-and...

Bacterial arthritis in pediatrics, key takeaways for pharmacy practice by Kenna Riley. www.instagram.com/p/DTvxxhOiUq... Full article available pharmacy.uconn.edu/pediatric-id... #Rxsky

A JAMA article titled "Influenza A(H3N2) Subclade K Virus Threat and Response" shows diagrams of the influenza virus, highlighting antigenic sites and amino acid changes. Labels indicate receptor-binding sites and glycosylation sites.

💬 Perspective: The rise of H3N2 subclade K may increase severe #influenza outcomes this season; available vaccines and antivirals remain important tools for prevention and treatment.

ja.ma/3MVJMt1

People at Increased Risk for Flu Complications Learn more about who is at higher risk of developing potentially serious flu complications.

4️⃣ 🚨 Treat early! Antivirals recommended for:
✔️ High-risk patients (incl children <2 / <5 yrs and adults ≥65 yrs)
✔️ Chronic medical conditions
✔️ Progressive disease
✔️ All hospitalized patients
🔗 Who is high risk? www.cdc.gov/flu/highrisk...
#PedsIDsky #RXsky

3️⃣ 🦠 Influenza A (H3N2) predominates
➡️ ~90% of subtyped isolates ( ~90% of these = K subtype)
Luckily! 💊 All tested strains remain susceptible to neuraminidase inhibitors (e.g., oseltamivir) and baloxavir
#PedsIDsky #RXsky